Alnylam expands board to 13, elects Peter N. Kellogg as Class II director

ALNYLAM PHARMACEUTICALS, INC.

Board expanded from 12 to 13 directors; Kellogg fills new vacancy effective March 7, 2023.
Kellogg will serve as Class II director until 2024 annual meeting and is expected to join the Audit Committee.
Non-employee director cash fee $55,000 (rising to $60,000 April 1, 2023); stock option for 4,948 shares at $194.34 strike.
Option vests ratably over three years; annual equity awards begin 2024 with $400,000 grant-date value.
Indemnification agreement entered with the Company consistent with other non-employee directors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Peter N. Kellogg

Director

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Effective: 2023-03-07
Filed: March 8, 2023, 6:59 PM ET

Effective as of March 7, 2023, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from twelve to thirteen and elected Peter N. Kellogg to fill the newly created vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter N. Kellogg was elected as Director at ALNYLAM PHARMACEUTICALS, INC..

Action: elected
Role: Director

Exact text from the filing

Effective as of March 7, 2023, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from twelve to thirteen and elected Peter N. Kellogg to fill the newly created vacancy.

View on SEC.gov

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-064580

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.